Unlocking the power of genomics with $66 million for research
Posted: 23 November 2023 The Albanese Government is unlocking the power and potential of personalised medicine with $66 million for genomics research into a number of serious diseases and common chronic conditions. The Albanese Government is unlocking the…
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Posted: 23 November 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the INSIGHT-003 trial has been expanded to four…
New Report: Actions Needed to Step Up Fight Against Superbug Pandemic Detailed
Posted: 22 November 2023 A new report from MTPConnect and its Australian Antimicrobial Resistance Network (AAMRNet) highlights the threat to human health posed by the rise of drug-resistant infections and presents recommendations that will equip the Australian healthcare…
Snow Centre for Immune Health to revolutionise global immunology research
Posted: 21 November 2023 The Snow Medical Research Foundation (Snow Medical) will establish one of the world’s leading immunology research centres at WEHI through a partnership with an initial commitment of $100 million over 10 years – one of the…
CSIRO study identifies AI models to improve automated chest X-ray diagnoses
Posted: 21 November 2023 New research from CSIRO, Australia’s national science agency, has identified methods for improving artificial intelligence (AI) diagnosis of heart and lung conditions using X-ray. In a recently published paper, scientists from CSIRO’s Australian e-Health Research…
4DMedical receives U.S. FDA clearance for CT LVAS
Posted: 21 November 2023 Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces that it has received clearance for its CT-based ventilation product (CT LVAS™) from the U.S. Food and Drug Administration (FDA). CT…
University of Melbourne unveils six start ups, announces $4.5M investment in company developing psychedelic-assisted therapies
Posted: 17 November 2023 The University of Melbourne has unveiled a cohort of six early-stage startups and announced the first syndicated investment of $4.5 million by the University’s Genesis Pre-Seed Fund and Tin Alley Ventures into a start-up…
Arovella Therapeutics partners with Cell Therapies to develop its ALA-101 manufacturing process for cancer clinical trials
Posted: 17 November 2023 Cell Therapies Pty Ltd is partnering with Arovella Therapeutics (ASX: ALA) to develop the manufacturing process for Arovella’s ALA-101 product candidate to treat cancer patients in upcoming clinical trials. The ALA-101 product incorporates Arovella’s…
Landmark blood test to detect silent, lethal cancer
Posted: 17 November 2023 Research that could lead to the first early detection blood test for pancreatic cancer has received critical funding from PanKind, The Australian Pancreatic Cancer Foundation. Pancreatic cancer is one of Australia’s biggest killers, with poor…
Monash harnesses new frontier in technology to propel promising local drug discoveries
Posted: 17 November 2023 The Monash Institute of Pharmaceutical Sciences (MIPS) has unveiled a brand new instrument – the Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer (MS) – which will play a key role in enabling the team to efficiently identify…
Monash University joins Uniseed to supercharge innovation success
Posted: 17 November 2023 Monash University has officially joined the Uniseed investment fund in a collaboration designed to enhance innovation opportunities by amplifying the growth of current and future startup and spinout companies. As a result of Monash…
Burnet Institute enters into a Research Licence and Option Agreement for Stellabody® – a biologic and antibody therapeutics platform – with argenx
Posted: 17 November 2023 Burnet Institute has entered into a research licence and option agreement for Burnet Institute’s Stellabody® technology with argenx. The Stellabody® platform Stellabody® is a unique on-target hexamerisation technology that exploits a natural property of…
